By Stephen Shields, MPH, and Elizabeth L. Ciemins, PhD, MA

Rates of type 2 diabetes (T2DM) continue to increase, and many individuals with T2DM do not meet recommended glycemic targets necessary to prevent micro- and macrovascular complications. At the same time, use of continuous glucose monitors (CGMs) has been increasing among patients with T2DM. However, the effects of real-time CGM on glycemia in primary care patients with T2DM, particularly among those not on intensive insulin therapy, have not been studied in real-world settings. In this prospective, embedded pragmatic clinical trial with retrospectively matched control patients, researchers sought to examine the association of real-time CGM use with glycemic control among individuals with T2DM receiving primary care.

Published Group Practice Journal, May/June 2023. ©AMGA

Share this Article: